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Background: Hormone sensitive lipase (HSL) promoter (LIPE-60 C > G) polymorphism has been found to be
involved in hepatic steatosis, obesity, diabetes and dyslipidemia. The precise interactions between these risk factors
and genetic susceptibility that may affect non-alcoholic fatty liver disease (NAFLD) are still not fully determined.
Methods: A cross-sectional study was conducted in 1056 men. To avoid the confounding effect of plasma
glucose, the study population was classified into normal glucose tolerance (NGT, n = 729) and glucose intolerance
(GI, n = 299) groups. NAFLD was diagnosed by abdominal ultrasound after ruling out any history of alcohol abuse.
A multivariate regression model was used to estimate the impact of these factors on NAFLD.
Results: In the NGT group, subjects with NAFLD often have complicated metabolic abnormalities. The coexistence
of NAFLD and GI has been demonstrated to have a synergistic effect raising BMI, serum insulin and HOMA-insulin
resistance (HOMA-IR). BMI and adipose-insulin resistance (Adipo-IR), but not HOMA-IR, significantly contributed to a
greater risk of developing NAFLD. Serum triglyceride was significantly up-regulated in men with the (CG + GG)
genotype of HSL promoter polymorphism, NAFLD and Adiopo-IR in sequence.
Conclusion: Adipo-IR, rather than HOMA-IR, appears to be a consistent insulin resistance index in the study of
NAFLD. G allele of the HSL promoter polymorphism may contribute the greatest impact raising serum triglyceride
in a state of glucose intolerance.
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Non-alcoholic fatty liver disease (NAFLD) is the most
prevalent chronic liver disease in the world, and is growing
especially quickly in Asia. It is regarded as a hepatic mani-
festation of metabolic syndrome (MetS) because of its close
concomitance with obesity, type 2 diabetes mellitus and
dyslipidemia [1,2]. Patients with NAFLD, who are at* Correspondence: kuoksfo@yahoo.com.tw
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reproduction in any medium, provided the orincreased risk of atherosclerotic cardiovascular disease, are
also at risk of progression to non-alcoholic steatotic hepa-
titis (NASH), cirrhosis or hepatocellular carcinoma [3,4].
Our previous study clearly documented a very high preva-
lence (57.8%) of fatty liver, as assessed by abdominal ultra-
sound, in adult Taiwanese [5]. Previous study has also shown
that compared to Caucasians, Asians (mostly Chinese) have
a greater fat accumulation in the body and viscera for a
given body mass index (BMI) [6]. Understanding the con-
sequences and how to prevent the development of fatty
liver are extremely important for Asians.
NAFLD, defined as hepatic steatosis with an intrahepatic
triglyceride (TG) content > 5% of the liver volume ortd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(FA) input and output. Physiologically, the hepatic TG
content results from a complex interaction of lipid
homeostasis, including (1) fatty acid influx derived by adi-
pose lipolysis (contributing 60% of hepatic FA), (2) dietary
fat intake from chylomicron (10- 15%), (3) de novo lipo-
genesis from plasma glucose (25- 30%), (4) fatty acid
β-oxidation and (5) fatty acid export by esterification to
secrete as a very low-density lipoprotein (VLDL) [7,8].
The mechanism of excess hepatic fat accumulation is
attributed generally to enhanced FA delivery from adipose
lipolysis and increased de novo lipogenesis in the liver itself,
while β-oxidation and VLDL export play minor roles [8].
Fatty acid synthase (FAS), catalyzing the final step in
FA biosynthesis, is well known to be the major deter-
minant of the generation of hepatic FA by de novo lipo-
genesis. Altered FAS expression has been correlated
with obesity related insulin resistance and hepatic
steatosis. Therefore, circulating FAS has been suggested
to be a possible surrogate marker of insulin resistance
[9,10]. In the FA metabolism, adipose triglyceride lipase
(ATGL) and hormone-sensitive lipase (HSL) are respon-
sible for > 95% of TG hydrolysis. Both ATGL and HSL
regulate the basal lipolysis, whereas only HSL deter-
mines the stimulated lipolysis. HSL, catalyzing diac-
ylglycerol and monoacylglycerol into free fatty acids,
determines the rate-limiting step to modulate complete
lipolysis [11,12]. HSL is also engaged in the mobilization
of FA from intracellular lipid stores in tissues. Insulin
represents the most potent inhibitor of HSL to shut
down lipolysis, and HSL expression has often been cor-
related with the pathogenesis of type 2 diabetes, abdo-
minal obesity and MetS [13-15]. Insulin resistance is the
pathophysiologic hallmark of the development of
NAFLD. As there is a very low expression of ATGL in
the liver, the activities of FAS and HSL seem to be essen-
tial for the regulation of fatty acid metabolism in the for-
mation of NAFLD.
Genetic susceptibility to hepatic lipid accumulation is
also considered important because of the evidence that
approximately one-third of NAFLD occurs in subjects
without the documented risk factors of obesity and insu-
lin resistance. The Ile 1483 variant of the FAS gene was
reported to have a protective effect, with a lower BMI,
waist hip ratio, fasting glucose and blood pressure [16].
The well-studied promoter variant of HSL (−60 C > G),
exhibiting a 40% decline in promoter activity, plays a
critical role in fat metabolism in some diseases in a sex-,
race- and insulin-dependent manner [17,18].
A combination of genetic and environmental risk fac-
tors, for example, diet, obesity or diabetes, is well known
to cause the development of NAFLD [4,19]. However,
the risk interaction and the relative impact on the devel-
opment of NAFLD of individual genes and relatedmetabolic biomarkers have not been thoroughly investi-
gated. We designed this study to clarify the impact of
metabolic abnormalities on the relationship between
fatty liver and glucose intolerance. The differential im-
pact of confounding risks for the development of
NAFLD was analyzed after stratification of the fasting
glucose. The results could have eventual clinical utility
to help establish a practical treatment strategy for




Subjects were recruited from the Department of Preventive
Medicine at KMUH in 2005 under the approval and super-
vision of the Institutional Review Board of Kaohsiung Me-
dical University Hospital (KMUH-IRB-980323). All of the
serum was obtained from the tissue bank in our hospital
and de-identified from participant’s names and personal
characteristics. To avoid gender bias, a cross-sectional
population of 1056 males was randomly enrolled within
3 months. The detailed medical history of each subject was
evaluated by an experienced physician. Twenty-seven par-
ticipants were excluded due to recognized dyslipidemia se-
condary to poorly-controlled DM, documented DM with
medication, Cushing’s syndrome, hypothyroidism, nephro-
tic syndrome, chronic liver disease, heavy alcohol use
(drinking more than once weekly) or use of lipid-lowering
agents. A total of 1029 male subjects were eligible for fur-
ther study, and were stratified by fasting glucose into nor-
mal glucose tolerance (NGT, < 100 mg/dl) and glucose
intolerance (GI, ≥ 100 mg/dl) groups.
Laboratory measurements
After overnight fasting, blood samples were collected and
analyzed for serum glucose, aspartate aminotransferase
(AST), alanine aminotransferase (ALT), total cholesterol,
serum triglyceride, HDL-cholesterol, and LDL-cholesterol,
using a multichannel autoanalyser. Serum insulin was
measured using commercial radioimmunoassay kits (Diag-
nostic Products Corporation, Los Angeles, CA, USA).
Serum non-esterified fatty acid (NEFA) was measured by
colorimetry (Wako Pure Chemical Industries, Ltd, Osaka,
Japan). The objectively quantitative expression of the rela-
tive hepatic insulin resistance was indicated by the homeo-
static model assessment of insulin resistance (HOMA-IR
index = insulin (μU/mL) × glucose (mmol/L)/22.5). The
adipose insulin resistance was expressed as the adipose in-
sulin resistance (Adipo-IR index = fasting serum NEFA
(μmol/L) × fasting serum insulin [μU/mL]) [20,21].
Search strategy
EDTA-treated blood samples were used for DNA extrac-
tion by standard methods. The TaqMan genotyping
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synthase FAS polymorphisms (rs2228305 for Ile1483Val,
rs2228307 for Val1888Ile) and HSL promoter poly-
morphism (rs34845087 for C-60G, LIPE 14672 C > G).
These assays were designed according to the SNP refer-
ence data in the NCBI GenBank database. The ABI
PRISM 7500® sequence detection system was use to de-
termine the sequence of the gene variants (Applied
Biosystems, Roche, Taipei, Taiwan).
Evaluation of fatty liver
Sonographic diagnosis of fatty liver was performed by
abdominal B-mode ultrasound (3.5 MHz convex trans-
ducer, Toshiba SSA-250; Toshiba, Tokyo, Japan) carried
out by experienced hepatologists trained at the same in-
stitution to ensure interobserver consistency. Diagnosis
of fatty liver was based on the brightness of the liver on
ultrasound as compared with the kidney, vascular blur-
ring of the hepatic vein trunk, and deep attenuation in
the right hepatic lobe. The absence of fatty liver change
(AFL) was defined as a normal echo texture without visible
fatty change. The presence of fatty liver (FL) was defined
as an increase in the fine echoes of hepatic parenchyma
with impaired visualization of the intrahepatic vessels
and diaphragm.
Statistical analysis
The SPSS 18.0 statistical package for Windows (SPSS Inc.,
Chicago, IL, USA) was used for all of the statistical ana-
lyses. Continuous variables were represented as the
means ± SD. Nonparametric tests (Kruskal–Wallis test
or Mann–Whitney rank-sum test) were used when the
original measurements were highly skewed. Allele fre-
quency was estimated by direct counting, while geno-
type distribution with Hardy–Weinberg equilibrium was
tested using the chi-square test. Two-way analysis of va-
riance (ANOVA, α = 0.05) was carried out to evaluate the
metabolic profiles by the interaction effects between fatty
liver and glucose intolerance. Student’s t-test with
Bonferroni comparisons post hoc analysis was conducted
within the NGT and GI groups. Multivariate regression
analysis was further employed using fatty liver as a
dependent variable, while body mass index (BMI),
HOMA-IR, Adipo-IR and HSL (GG + GC vs CC) geno-
type were selected as independent variables based on sig-
nificance in univariate analyses. To avoid multicollinearity
in the regression model, serum insulin and NEFA were
not included as independent variables in the multivariate
regression model. Separate multiple regression analyses
stratified by fasting glucose were further used to evaluate
the effects of BMI, HOMA-IR, Adipo-IR, fatty liver, and
HSL promoter genotypes (GG + GC vs CC) on serum
TG. In addition, to compare the parameter estimates be-
tween NGT and GI, a single multiple regression modelwas conducted with the additional interactions of glucose
intolerance vs BMI, HOMA-IR, Adipo-IR, fatty liver, and
HSL promoter (GG + GC vs CC). Statistical significance
was defined as a P value of < 0.05 using a two-tailed test.
Results
To standardize the de novo lipogenesis by fasting plasma
glucose, our purely male population was divided into
NTG (n = 729) and GI (n = 299) groups. The age of the
participants ranged from 20 to 70 years, the majority
(>80%) being distributed in the range of 40–65 years. The
prevalence of GI was 29.1% in our adult population. There
was a high prevalence of MetS abnormalities (obesity
30.6%, GI 29.1%, hyperTG 42.2%, low HDL-C 19.6% and
hypertension 51.6%) in subjects with NAFLD. Minor allele
A of FAS (Val1483Ile) and G of FAS (Val1888Ile) poly-
morphism was nearly absent, with a monogenic distribu-
tion of Val1483 (99.6%) and Val 1888 (100%). The genetic
effect of FAS was not further analyzed in the development
of fatty liver. The frequency of the minor G allele of the
HSL promoter (−60 C > G) was 9.9%, while the genotype
frequency of CC: CG: GG was distributed as 80.8: 18.4 :
0.8% in Hardy–Weinberg equilibrium. There was no sig-
nificant difference in the frequency distribution of the
HSL promoter (−60 C > G) genotype between the NGT
and GI groups.
As shown in Table 1, the prevalence of FL (67.2%) in the
GI group was significantly higher than in the NGT group
(55.7%) (p = 0.001, chi-square test). Within the NGT or GI
groups, there were significantly greater metabolic abnor-
malities in the presence of FL. The metabolic profiles,
such as BMI, serum insulin and HOMA-IR, were signifi-
cantly attributed to a synergistic effect of FL and GI. How-
ever, the metabolic abnormalities in the group of NGT
and FL seemed equivalent or even worse than those in the
GI group without FL. The metabolic abnormalities oc-
curred more in the presence of FL.
In the development of FL, risk analysis was conducted
to compare the odds ratios of BMI, HOMA-IR, Adipo-
IR and HSL promoter genotypes (CC vs CG + GG)
(Table 2). Analysis showed that BMI and Adipo-IR, ra-
ther than HOMA-IR and HSL promoter polymorphism,
are independent risk factors for the formation of FL.
Obesity plays a central role in MetS. Our study demon-
strated that the frequency of FL and the metabolic profiles
of MetS were positively parallel to BMI, with the exception
of GI (Table 3). The frequency of FL is greater than that of
GI for a given BMI. Relevant metabolic abnormalities, in-
cluding 38.4% for fatty liver, 33.4% for hypertension, 26.4%
for glucose intolerance, 18.2% for hypertriglyceridemia
and 10.1% for low HDL-C, existed in normal BMI sub-
jects; this has previously been regarded as metabolic obese
normal weight (MONW). This means that hepatic
steatosis is not only dependent on the BMI status, and the
Table 1 Comparison of the metabolic abnormalities between glucose tolerance and fatty liver
Groups/variables Normal Glucose Tolerance (NGT) Glucose Intolerance (GI) P for effect
of FL vs AFL
P for effect
of GI vs NGT
P for interaction








Age (yrs) 45.63 ± 8.10 44.60 ± 8.65 48.68 ± 6.89 49.21 ± 8.69 0.675 < 0.0001 0.195
BMI (kg/m2) 23.16 ± 2.51 25.64 ± 3.06* 22.79 ± 3.31 26.16 ± 3.03* < 0.0001 0.716 0.035
Serum insulin (μIU/ml) 2.22 ± 2.47 4.28 ± 4.48* 3.77 ± 6.73 7.74 ± 12.00* < 0.0001 < 0.0001 0.044
NEFA (μmol/L) 509.81 ±192.78 575.03 ± 227.93* 589.47 ±230.07 646.75 ± 264.183 < 0.0001 < 0.0001 0.811
HOMA-IR 0.48 ± 0.53 0.94 ± 0.99* 1.28 ± 2.89 2.47 ± 4.49* < 0.0001 < 0.0001 0.027
Adipo-IR 1.11 ± 1.22 2.57 ± 3.95* 2.10 ± 3.86 4.50 ± 5.24* < 0.0001 < 0.0001 0.083
SBP (mmHg) 123.5 ± 15.3 126.2 ±15.1* 126.86 ± 16.86 130.44 ±18.20 0.007 0.001 0.701
DBP (mmHg) 76.2 ± 10.9 79.1 ± 10.6* 78.55 ± 11.49 82.45 ± 11.83* < 0.0001 < 0.0001 0.530
AST (IU/L) 27.20 ±11.81 29.97 ± 11.41* 28.77 ±16.31 34.22 ± 18.71* < 0.0001 0.004 0.163
ALT (IU/L) 25.28 ± 19.78 34.35 ± 20.64* 25.94 ± 20.91 40.70 ± 33.01* < 0.0001 0.037 0.090
Cholesterol (mg/dl) 175.13 ± 31.00 184.24 ± 32.65* 173.98 ± 28.97 188.17 ± 34.57* < 0.0001 0.548 0.274
Triglyceride (mg/dl) 104.78 ± 58.24 158.29 ± 115.18* 129.99 ± 111.28 163.97 ± 102.82* < 0.0001 0.028 0.165
HDL-C (mg/dl) 53.75 ± 12.87 49.12 ± 11.55* 50.09 ± 10.67 48.30 ± 10.68 0.002 0.034 0.176
LDL-C (mg/dl) 115.27 ± 31.50 130.27 ± 32.97* 117.23 ± 28.96 129.08 ± 33.12* < 0.0001 0.895 0.584
*P < 0.025 = 0.05/2 (Bonferroni test, two sample comparison within the normal glucose tolerance and glucose intolerance groups).
AFL indicates absence of fatty liver, FL indicates fatty liver. BMI indicates body mass index. SBP and DBP indicate systolic and diastolic blood pressure.
NEFA indicates non-esterified fatty acid.
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greatly between individuals.
Power calculation was more than 80% in the whole
population when the pooled standard deviation of TG is
estimated around 90 mg/dl. In the NGT group, the pres-
ence of FL followed by high Adipo-IR and BMI signifi-
cantly contributed to a raised serum TG (Table 4).
However, the effect of BMI on serum TG disappeared in
the GI group. Conversely, the HSL promoter genotype
(CG + GG vs CC) demonstrated a significant strong im-
pact elevating serum TG in the GI but not the NGT
group. Comparison of the parameter estimates of the
impact on serum TG, indicated by interactions, showedTable 2 Logistic regression using fatty liver as a
dependent variable in normal glucose tolerance and
glucose intolerance groups
Independent variables Odds ratio P value
Normal glucose tolerance
BMI 1.31 (1.22-1.41) < 0.0001
HOMA-IR 0.98 (0.55-1.77) 0.948
Adipo-IR 1.36 (1.06-1.75) 0.016
HSL promoter genotype (CC vs CG + GG) 1.41 (0.71-2.16) 0.122
Glucose intolerance
BMI 1.50 (1.32-1.69) < 0.0001
HOMA-IR 0.85 (0.64-1.13) 0.258
Adipo-IR 1.41 (1.11-1.78) 0.005
HSL promoter genotype (CC vs CG + GG) 1.03 (0.49-2.18) 0.940a significant difference in the HSL promoter (GG +
GC vs CC) (p = 0.005) between the NGT and the GI
groups. Therefore, it means that the TG level is very
dependent upon the status of the subject’s glucose in-
tolerance or not.
Discussion
Our study demonstrated that BMI and Adipo-IR signifi-
cantly contributed to FL formation. Men’s BMI is
reported to predict approximately 93% of the variance
linked to obesity-related adipocyte size, fat cell mass and
fat distribution [22]. Accordingly, BMI could be used as
a clinically practical parameter in males to represent the
obesity-related fat metabolism. There is substantial evi-
dence that obesity is related to excess fat cell mass lead-
ing to increased basal lipolysis [11]. Insulin resistance is
well-documented as the hallmark of MetS, but occursTable 3 Prevalence of fatty liver and indexes of metabolic
syndrome by BMI status







Fatty liver 38.4% 67.3% 86.1% < 0.0001
Hypertension 33.4% 53.0% 57.9% < 0.0001
Glucose intolerance 26.4% 29.2% 34.9% 0.086
Hypertriglyceridemia 18.2% 37.4% 49.3% < 0.0001
HDL < 40 mg/dl 10.1% 22.6% 24.6% < 0.0001
Hypertension is defined as systolic BP ≥ 130 or diastolic BP ≥ 80 mmHg.
Glucose intolerance is defined as fasting glucose ≥ 100 mg/dl.
Hypertriglyceridemia is defined as fasting triglyceride ≥ 150 mg/dl.




95% Confidence interval P value
Lower bound Upper bound
Normal glucose tolerance
BMI 4.30 2.41 6.20 < 0.0001
HOMA-IR −31.06 −41.11 −21.01 < 0.0001
Adipo-IR 17.04 14.35 19.74 < 0.0001
FL vs AFL 27.50 16.41 38.58 < 0.0001
HSL promoter genotype (CG + GG vs CC) −3.05 −16.14 10.04 0.648
Glucose intolerance
BMI −0.32 −3.82 3.82 0.860
HOMA-IR −11.01 −16.26 −5.76 < 0.0001
Adipo-IR 11.50 7.04 15.96 < 0.0001
FL vs AFL 29.40 3.74 55.05 0.025
HSL promoter genotype (CG + GG vs CC) 34.10 9.16 60.04 0.010
FL indicates fatty liver, AFL indicates absence of fatty liver.
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such as adipose, liver and muscle tissues to a given insu-
lin level [23]. The Adipo-IR index is a simple way of
measuring the inhibiting response of lipolysis by insulin
in adipose tissue. Our results rationally suggest that
people with a higher BMI usually have a greater fat cell
mass, increased basal lipolysis leading to higher NEFA
and greater insulin resistance (represented by Adipo-IR),
which will result in hepatic FFA overflow and FL forma-
tion. The genetic effect of the HSL promoter (CC vs CG +
GG) in relevant lipolysis and FL formation may be over-
come by the greater impact of obesity-related lipolysis and
insulin resistance of adipose (Adipo-IR). This finding is
compatible with the fact that increased plasma FFA from
adipose lipolysis is the major provider of lipids in the
steatotic liver [8,20,24].
NAFLD has been regarded as the hepatic manifest-
ation of MetS. However, debate continues regarding the
progression of MetS to NAFLD or vice versa [25,26].
NAFLD has been reported to be a better independent
risk factor for cardiovascular disease than MetS in some
studies [3,27]. Liver fat is an independent determinant of
the hepatic glucose output, which is sensitive to insulin.
The liver is the primary site regulating 50-70% of insulin
clearance [28]. Increased hepatic steatosis is associated
with impaired insulin clearance and hepatic insulin re-
sistance, which results in plasma glucose elevation, com-
pensatory hyperinsulinemia and progression to type 2
DM. Hepatic insulin resistance also accelerates VLDL se-
cretion, contributing to hypertriglyceridemia and low-
HDL cholesterol concentration. Thus, hyperinsulinemia
is regarded to be a consequence rather than a cause of
NAFLD. Furthermore, hyperinsulinemia, stimulating thesympathetic tone and enhancing renal sodium reabsorp-
tion, contributes to hypertension [28,29]. HOMA-IR, an
indirect estimate of insulin resistance, is usually used to
represent the inhibition of hepatic glucose output by in-
sulin, which is maintained by a balance between the liver
and β-cells [20]. As suggested by Kotronen et al., the
HOMA-IR index, which overestimates the insulin resist-
ance in subjects with NAFLD, is more likely to reflect
impaired insulin clearance and secretion than insulin
sensitivity [29]. Our results revealed an inconsistent ef-
fect of HOMA-IR, whereas Adipo-IR showed a consist-
ent trend in regulating NAFLD formation or serum TG.
This highly suggests Adipo-IR as an index of insulin sen-
sitivity in NAFLD or MetS research. In our study, sub-
jects with FL and NGT complicated more metabolic
abnormalities than subjects with AFL and GI. The coex-
istence of FL and GI exerts a significant synergistic ef-
fect raising BMI, serum insulin and HOMA-IR. This
indicates that FL may develop earlier in the progression
of MetS and the coexistence of FL and GI may magnify
obesity and insulin resistance.
No matter how MetS is defined, visceral obesity is an
obligatory component of MetS based on the recommen-
dations of the International Diabetes Federation consen-
sus [30]. However, there is still no convenient, practical
worldwide indicator to define visceral obesity. As our
study has shown, metabolic abnormalities are consider-
ably prevalent in a MONW population. Visceral obesity
is not easily defined by BMI alone since the threshold
for hepatic lipid accumulation (a critical visceral adipos-
ity) differs individually [4]. The liver is a pivotal organ to
regulate the homeostasis of fat and glucose. It also plays
a central role linking the interaction of obesity, GI,
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shown that hepatic steatosis rather than extrahepatic
adiposity is more correlated with insulin resistance, es-
pecially in normal-weight non-diabetic subjects. NAFLD
is an early manifestation of MetS and its severity is posi-
tively parallel to the degree of obesity. Therefore, hepatic
steatosis may be the earliest sign in the pathogenesis
of MetS and may be a better marker of visceral obesity
for defining MetS, especially in a MONW population
[4,26,31]. Compared with the gold standard of liver bi-
opsy to diagnose FL, abdominal ultrasound is a noninva-
sive, convenient and accurate tool with high sensitivity
and specificity. Therefore, we propose that a steatotic
liver evaluated by ultrasound is a more sensitive indica-
tor than BMI for defining visceral obesity.
Facing an increased FA influx and de novo lipogenesis,
the hepatic FA pool is regulated by β-oxidation, with
biosynthesis of TG for secretion as VLDL-C particles or
storage as intrahepatic lipid. Current evidence suggests
that hepatic TG synthesis and VLDL-TG secretion pro-
tect against lipotoxicity by buffering hepatic FFA influx
[8]. Fasting serum TG is carried predominantly in the
particles of VLDL secreted from the liver, which is
inhibited by insulin. In subjects without FL, nearly 70%
of FA incorporated into VLDL-TG is derived from
plasma FA sources, and the rest originates from hepatic
de novo lipogenesis and lipolysis of intrahepatic lipids.
The VLDL-TG secretion rate is greater in subjects with
FL than those without FL [4,7]. Our results demon-
strated that the impact of increased circulating TG is
significantly regulated by the presence of FL, Adipo-IR
and BMI in sequence. This is compatible with the
reported fact that a higher BMI, greater insulin resist-
ance to adipose (Adipo-IR) and more liver fat is com-
pensated with higher secretion of VLDL-TG [4,7,8,30].
Therefore, the presence of FL essentially could result in
dyslipidemia and related atherosclerosis. Our results
demonstrated a differential intensity of HOMA-IR inhib-
ition of VLDL-TG secretion in the NGT and GI groups.
In the GI state, it still demonstrated an inhibiting impact
on VLDL-TG secretion coexistent with the impaired
hepatic output in a given HOMA-IR, which implies dif-
ferential insulin sensitivity to regulate fat and glucose
metabolism in the liver, such as by inhibiting VLDL-TG
secretion and hepatic glucose output. However, greater
insulin resistance has been shown to lead to greater
VLDL-TG secretion and higher serum TG [12-14]. Thus
our variable TG regulation responses when using
HOMA-IR as an insulin resistance index suggest the
need for a more appropriate index to represent insulin
resistance for glucose or fatty acid metabolism. Adipo-IR,
representing the circulating FFA influx relative to insulin,
can be regarded as a good indicator of insulin resistance
in studies of TG metabolism and NAFLD.There are many reports in the literature investigating
C-60G gene polymorphism in the HSL promoter. The
Ely study showed a gender specific effect on insulin and
lipid levels in–60G carriers. Men carrying the –60G al-
lele had significantly lower fasting NEFA and LDL-
cholesterol than non-carriers [18]. Ordovas et al.
reported that male carriers of the –60G allele who were
not alcohol drinkers had higher glucose levels than non-
carriers [32]. In addition, the C-60G polymorphism is
associated with increased waist circumference in lean
subjects [33]. The interaction between body fat mass
and physical activity is closely associated with the C-60G
polymorphism in male carriers. The Quebec Family
study showed that men who were G allele carriers were
less likely to lose adiposity by physical activity than non-
carriers [34]. Talmud et al. found no significant differ-
ence in fasting lipid, glucose, BMI, waist/hip ration or
blood pressure between C and G allele carriers but the
G allele carriers had significant lower HOMA index in
healthy young men [35]. Taken together, these previous
reports reveal that HSL promoter polymorphisms play a
critical role in the regulation of fat and glucose metabol-
ism and are also highly correlated with insulin resist-
ance. The apparent discrepancies between these studies,
however, are hard to rationally explain via pathophysio-
logic mechanisms. To avoid confounding effects, multi-
variate regression analysis was carried out focusing only
on male gender stratified by fasting glucose so insulin
resistance is clearly defined. Our results demonstrated
different impacts on serum TG by insulin resistance,
BMI and the HSL promoter genotype after stratification
by serum glucose. Since serum insulin, HOMA-IR and
BMI were significantly attributable to a synergistic effect
of glucose intolerance and FL, it is necessary to compare
the interaction of these confounding factors together on
serum TG. We observed no difference in anthropomet-
ric or metabolic parameters and related insulin resist-
ance indexes between genotype (CG + GG) and (CC)
carriers in the NTG group, except for significantly
higher serum TG levels found in carriers of the G allele
in the GI group (Additional file 1: Table S1 and S2).
Recent evidence has shown that the accumulation of
diacylglycerol in the liver might activate protein kinase
C, induce insulin resistance and increase VLDL-TG se-
cretion. HSL is involved in a rate-limiting step to
catalyze diacylglycerol and monoacylglycerol into free
fatty acids, so HSL activity determines the tissue content
of diacylglycerol and the degree of insulin resistance
[20,26]. Reid et al. found that hepatic overexpression of
HSL promotes β-oxidation of the fatty acid to ameliorate
steatosis [36]. Taken together, HSL activity has a critical
role in the development of NAFLD. The G allele of the
HSL promoter (C-60G) exhibited a 40% decline in pro-
moter activity, which may theoretically cause greater
Hsiao et al. BMC Medical Genetics 2013, 14:54 Page 7 of 8
http://www.biomedcentral.com/1471-2350/14/54accumulation of diacylglycerol in the liver. This could
lead to greater insulin resistance, less β-oxidation and
more VLDL-TG secretion. The HSL activity is negatively
regulated by insulin and up-regulated by glucose. There
are multiple prominent cis-regulatory elements, includ-
ing the insulin response element (IRE), glucose response
element (GRE) and fat specific element (FSE), along with
other transcriptional factor binding elements, residing in
the proximal promoter regions of the human HSL gene.
All these cis-acting elements act as critical transcrip-
tional regulators for promoter activity [37,38]. A litera-
ture review by Ling et al. pointed out that the epigenetic
effect of DNA methylation always occurs in CG dinucle-
otides and is modified by environmental exposure to
nutrients in complex multifactorial diseases such as type
2 DM. The relative ratio of insulin, glucose and fat levels
may act on the cis-regulating elements to modulate
promoter function and transcriptional initiation [39].
Our results showed a genetic effect of the HSL pro-
moter (C-60G) regulating serum TG only in the GI
group and not in the NGT group. It is rational to specu-
late that the G allele of the HSL promoter may express a
differential susceptibility to the complex interaction be-
tween serum insulin, glucose and fat to determine lipoly-
sis, such as lowering lipolytic activity only under a
dependable range of insulin resistance. Because this is a
cross-sectional study, further prospective and large-scaled
study is suggested to verify this preliminary observation.
Conclusion
The risk interaction between genetic susceptibility, obes-
ity and insulin resistance contribute different impacts on
the development of NAFLD. Adipo-IR, rather than
HOMA-IR, is proposed as a consistent insulin resistance
index for the study of NAFLD. BMI and Adipo-IR were
independent risk factors for the formation of FL. In a GI
state, HSL promoter (CG + GG) contributed the greatest
impact on raising serum TG, followed by FL and Adipo-
IR in sequence.
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